logo

For the Inventor, By the Inventor

Calgary, Canada

Resverlogix Corporation


USPTO Granted Patents = 23

% Expired Patents = 30.4



Trademarks = 1

Forward Citations = 296

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Henrik C Hansen (17 out of 18 patents)

silverMedal Norman C W Wong (5 out of 5 patents)

bronzeMedal Fabrizio S Chiacchia (5 out of 5 patents)

4.  David Robert McCaffrey (4 out of 5 patents)

5.  Joseph E L Tucker (4 out of 4 patents)

6.  Ewelina B Kulikowski (3 out of 3 patents)

7.  Dean E Gilham (2 out of 2 patents)

8.  Sylwia Wasiak (2 out of 2 patents)

9.  Christopher R A Halliday (2 out of 2 patents)

10.  Narmada R Shenoy (2 out of 6 patents)

11.  Aziz Naeem Khan (2 out of 2 patents)

12.  Christopher Ross Armstrong Halliday (2 out of 5 patents)

13.  Kenneth Eugene Lebioda (2 out of 5 patents)

14.  Jan Johansson (1 out of 9 patents)

15.  Gregory Steven Wagner (1 out of 18 patents)


23 patents:

1. 12673059 - Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor (2026-07-07),
2. 12551484 - Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor (2026-02-17),
3. 11407719 - Anti-inflammatory agents (2022-08-09),
4. 10882828 - Anti-inflammatory agents (2021-01-05),
5. 10772894 - Compositions and therapeutic methods for the treatment of complement-associated diseases (2020-09-15),
6. 10532054 - Compounds for the prevention and treatment of cardiovascular diseases (2020-01-14),
7. 10131640 - Anti-inflammatory agents (2018-11-20),
8. 10111885 - Compositions and therapeutic methods for the treatment of complement-associated diseases (2018-10-30),
9. 10016426 - Pharmaceutical compositions for substituted quinazolinones (2018-07-10),
10. 9757368 - Anti-inflammatory agents (2017-09-12),
11. 9610251 - Pharmaceutical compositions for substituted quinazolinones (2017-04-04),
12. 9238640 - Anti-inflammatory agents (2016-01-19),
13. 9199990 - Compounds for the prevention and treatment of cardiovascular diseases (2015-12-01),
14. 8952021 - Compounds for the prevention and treatment of cardiovascular disease (2015-02-10),
15. 8889698 - Compounds for the prevention and treatment of cardiovascular diseases (2014-11-18),
Resverlogix Corporation (Resverlogix) is a biotechnology company focused on developing innovative therapies for patients with chronic diseases. With a strong emphasis on epigenetics, Resverlogix is dedicated to discovering and advancing novel small molecule therapeutics that target epigenetic pathways in order to address unmet medical needs. The company's lead product candidate, Apabetalone, is being investigated as a potential treatment for cardiovascular and other chronic diseases with significant unmet needs. Resverlogix's mission is to improve patients' quality of life and potentially extend their lifespan by developing breakthrough treatments.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Resverlogix Corporation
23 Patents

#45 in Calgary

#629 in Canada

#27,581 in the World

Calgary, CA
Calgary, Canada

Resverlogix Corporation

Forward Citations = 296

25 inventors:

goldMedal Henrik C Hansen (17 out of 18 patents)

silverMedal Norman C W Wong (5 out of 5 patents)

bronzeMedal Fabrizio S Chiacchia (5 out of 5 patents)

4.  David Robert McCaffrey (4 out of 5 patents)

5.  Joseph E L Tucker (4 out of 4 patents)

Please report any incorrect information to [email protected]
Loading…